Sangamo Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OTC.Pink
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.38% of Sangamo Therapeutics, Inc.'s common stock, filing as a Schedule 13G.
OTC.Pink
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 9.75% of Sangamo Therapeutics, Inc. common stock as of March 31, 2026.
OTC.Pink
Wasatch Advisors LP filed an Amendment No. 9 to Schedule 13G, reporting a 2.1% beneficial ownership stake in Sangamo Therapeutics Inc. as of September 30, 2025.
OTC.Pink
Wasatch Advisors LP, an investment adviser, has filed an amended Schedule 13G, reporting a passive beneficial ownership of 5.2% in Sangamo Therapeutics, Inc. as of March 31, 2025.
OTC.Pink
Wasatch Advisors LP has filed an amended Schedule 13G, reporting a 6.6% beneficial ownership stake in Sangamo Therapeutics, Inc. as of December 31, 2024.